Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like ...

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Obesity late-comer Amgen announced full results from Part 1 of the Phase II study of MariTide (maridebart cafraglutide, ...

The new weight loss drug which is set to give Ozempic and Mounjaro a run for their money, MariTide, is taken on a monthly ...

Amgen Inc. ( NASDAQ: AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ET Justin Claeys - Vice President of Investor Relations James Bradner - Executive Vice President of Research & ...